{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:41:36Z","timestamp":1774024896672,"version":"3.50.1"},"reference-count":35,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMedLife"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.25122\/jml-2023-0342","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:39:22Z","timestamp":1737689962000},"page":"800-805","source":"Crossref","is-referenced-by-count":4,"title":["Medication-related burden among Iraqi patients with ulcerative colitis: a cross-sectional study"],"prefix":"10.25122","volume":"17","author":[{"given":"Nawar Abdulridha","family":"Abood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dheyaa Jabbar","family":"Kadhim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad Jawad","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Gastroenterology and Hepatology Teaching Hospital, Baghdad Medical City, Baghdad, Iraq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10755","reference":[{"issue":"10","key":"ref1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jamapediatrics.2017.2571","article-title":"The role of environmental factors in the pathogenesis of inflammatory bowel diseases","volume":"171","author":"Shouval DS, Rufo PA","year":"2017","unstructured":"1. Shouval DS, Rufo PA, The role of environmental factors in the pathogenesis of inflammatory bowel diseases, JAMA Pediatr, 2017;171(10):999","journal-title":"JAMA Pediatr"},{"issue":"11","key":"ref2","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3390\/jcm8111970","article-title":"History of inflammatory bowel diseases","volume":"8","author":"Actis GC, Pellicano R, Fagoonee S, Ribaldone DG","year":"2019","unstructured":"2. Actis GC, Pellicano R, Fagoonee S, Ribaldone DG, History of inflammatory bowel diseases, J Clin Med, 2019;8(11):1970","journal-title":"J Clin Med"},{"issue":"4","key":"ref3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.trsl.2012.01.001","article-title":"Biomarkers in inflammatory bowel disease: current practices and recent advances","volume":"159","author":"Iskandar HN, Ciorba MA","year":"2012","unstructured":"3. Iskandar HN, Ciorba MA, Biomarkers in inflammatory bowel disease: current practices and recent advances, Transl Res, 2012;159(4):313-325","journal-title":"Transl Res"},{"issue":"9","key":"ref4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/17474124.2018.1503052","article-title":"Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East","volume":"12","author":"Sharara AI, Al Awadhi S, Alharbi O, Al Dhahab H, Mounir M, Salese L","year":"2018","unstructured":"4. Sharara AI, Al Awadhi S, Alharbi O, Al Dhahab H, Mounir M, Salese L, Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East, Expert Rev Gastroenterol Hepatol, 2018;12(9):883-897","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/20905068.2019.1592938","article-title":"Interleukin-1 single nucleotide polymorphisms as risk factors for susceptibility of inflammatory bowel disease: an Iraqi Arab population-based study","volume":"55","author":"Ad\u2019hiah AH, Hessan EB, Shahab BA","year":"2019","unstructured":"5. Ad\u2019hiah AH, Hessan EB, Shahab BA, Interleukin-1 single nucleotide polymorphisms as risk factors for susceptibility of inflammatory bowel disease: an Iraqi Arab population-based study, Arab J Gastroenterol, 2019;55(1):1-6","journal-title":"Arab J Gastroenterol"},{"issue":"1","key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43042-021-00158-9","article-title":"Genetic polymorphism of HLA-G gene (G01:03, G01:04, and G*01:05N) in Iraqi patients with inflammatory bowel disease (ulcerative colitis and Crohn\u2019s disease)","volume":"22","author":"Abdul-Hussein SS, Ali EN, Zaki NH, Ad\u2019hiah AH","year":"2021","unstructured":"6. Abdul-Hussein SS, Ali EN, Zaki NH, Ad\u2019hiah AH, Genetic polymorphism of HLA-G gene (G01:03, G01:04, and G*01:05N) in Iraqi patients with inflammatory bowel disease (ulcerative colitis and Crohn\u2019s disease), Egypt J Med Hum Genet, 2021;22(1):1-9","journal-title":"Egypt J Med Hum Genet"},{"key":"ref7","article-title":"The role of diet, prebiotic and probiotic in the development and management of inflammatory bowel diseases (IBD)","author":"Abdulamir AS, Zaman MZ, Hafidh RR, Bakar FA, Karoui S","year":"2012","unstructured":"7. Abdulamir AS, Zaman MZ, Hafidh RR, Bakar FA, Karoui S, The role of diet, prebiotic and probiotic in the development and management of inflammatory bowel diseases (IBD), Inflammatory Bowel Disease. Advances in Pathogenesis and Management, 2012;Available from: https:\/\/books.google.iq\/books?id=mZmfDwAAQBAJ&pg=PA249","journal-title":"Inflammatory Bowel Disease. Advances in Pathogenesis and Management"},{"issue":"3","key":"ref8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000518003","article-title":"Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab world: a systematic review and meta-analysis","volume":"6","author":"Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F, Danese S","year":"2021","unstructured":"8. Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F, Danese S, Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab world: a systematic review and meta-analysis, Inflamm Intest Dis, 2021;6(3):123-131","journal-title":"Inflamm Intest Dis"},{"issue":"7","key":"ref9","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jfma.2018.07.005","article-title":"Inflammatory bowel disease and its treatment in 2018: global and Taiwanese status updates","volume":"118","author":"Su HJ, Chiu YT, Chiu CT, Lin YC, Wang CY, Hsieh JY","year":"2019","unstructured":"9. Su HJ, Chiu YT, Chiu CT, Lin YC, Wang CY, Hsieh JY, Inflammatory bowel disease and its treatment in 2018: global and Taiwanese status updates, J Formos Med Assoc, 2019;118(7):1083-1092","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000505092","article-title":"Ulcerative colitis: disease burden, impact on daily life, and reluctance to consult medical professionals: results from a Japanese internet survey","volume":"5","author":"Hibi T, Ishibashi T, Ikenoue Y, Yoshihara R, Nihei A, Kobayashi T","year":"2020","unstructured":"10. Hibi T, Ishibashi T, Ikenoue Y, Yoshihara R, Nihei A, Kobayashi T, Ulcerative colitis: disease burden, impact on daily life, and reluctance to consult medical professionals: results from a Japanese internet survey, Inflamm Intest Dis, 2020;5(1):27-35","journal-title":"Inflamm Intest Dis"},{"issue":"9","key":"ref11","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/jcm11092302","article-title":"An update on current pharmacotherapeutic options for the treatment of ulcerative colitis","volume":"11","author":"Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S","year":"2022","unstructured":"11. Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S, An update on current pharmacotherapeutic options for the treatment of ulcerative colitis, J Clin Med, 2022;11(9):2302","journal-title":"J Clin Med"},{"issue":"6","key":"ref12","doi-asserted-by":"publisher","first-page":"101606","DOI":"10.1016\/j.disamonth.2023.101606","article-title":"Ulcerative colitis: addressing the manifestations, the role of fecal microbiota transplantation as a novel treatment option and other therapeutic updates","volume":"69","author":"Dheyaa M, Vora N, Dheyaa A, Pati S, Narreddy M, Patel P","year":"2023","unstructured":"12. Dheyaa M, Vora N, Dheyaa A, Pati S, Narreddy M, Patel P, Ulcerative colitis: addressing the manifestations, the role of fecal microbiota transplantation as a novel treatment option and other therapeutic updates, Dis Mon, 2023;69(6):101606","journal-title":"Dis Mon"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/PROM.S245534","article-title":"Factors associated with medication-related burden quality of life (MRB-QoL) in community-dwelling adults with long-term conditions: an exploratory study","volume":"12","author":"Mohammed MA, Moles RJ, Chen TF","year":"2021","unstructured":"13. Mohammed MA, Moles RJ, Chen TF, Factors associated with medication-related burden quality of life (MRB-QoL) in community-dwelling adults with long-term conditions: an exploratory study, Patient Relat Outcome Meas, 2021;1255-63","journal-title":"Patient Relat Outcome Meas"},{"issue":"15","key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14656566.2021.1978977","article-title":"How should a physician assess medication burden and polypharmacy?","volume":"22","author":"Iqbal A, Matthews F, Hanratty B, Todd A","year":"2021","unstructured":"14. Iqbal A, Matthews F, Hanratty B, Todd A, How should a physician assess medication burden and polypharmacy?, Expert Opin Pharmacother, 2021;22(15):1-4","journal-title":"Expert Opin Pharmacother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3389\/fphar.2020.01296","article-title":"Medication-related burden and medication adherence among geriatric patients in Kuwait: a cross-sectional study","volume":"11","author":"Awad A, Alhadab A, Albassam A","year":"2020","unstructured":"15. Awad A, Alhadab A, Albassam A, Medication-related burden and medication adherence among geriatric patients in Kuwait: a cross-sectional study, Front Pharmacol, 2020;111296","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/PROM.S44694","article-title":"A systematic review of patient-reported measures of burden of treatment in three chronic diseases","volume":"7","author":"Eton D, Elraiyah TA, Yost K, Ridgeway J, Johnson A, Egginton J","year":"2013","unstructured":"16. Eton D, Elraiyah TA, Yost K, Ridgeway J, Johnson A, Egginton J, A systematic review of patient-reported measures of burden of treatment in three chronic diseases, Patient Relat Outcome Meas, 2013;77-15","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018880","article-title":"Development and validation of an instrument for measuring the burden of medicine on functioning and well-being: the Medication-Related Burden Quality of Life (MRB-QoL) tool","volume":"8","author":"Mohammed MA, Moles RJ, Hilmer SN, O'Donnel LK, Chen TF","year":"2018","unstructured":"17. Mohammed MA, Moles RJ, Hilmer SN, O'Donnel LK, Chen TF, Development and validation of an instrument for measuring the burden of medicine on functioning and well-being: the Medication-Related Burden Quality of Life (MRB-QoL) tool, BMJ Open, 2018;8(1):","journal-title":"BMJ Open"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.12688\/f1000research.124698.2","article-title":"Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a cross-sectional study","volume":"11","author":"Abbas HK, Kadhim DJ, Gorial FI, Shareef LG","year":"2022","unstructured":"18. Abbas HK, Kadhim DJ, Gorial FI, Shareef LG, Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a cross-sectional study, F1000Res, 2022;11970","journal-title":"F1000Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.12688\/f1000research.124941.1","article-title":"Medication-related burden among patients with diabetes mellitus and its relation to diabetic control parameters: an observational study","volume":"11","author":"Noori AJ, Kadhim DJ, Al-Hilal MA","year":"2022","unstructured":"19. Noori AJ, Kadhim DJ, Al-Hilal MA, Medication-related burden among patients with diabetes mellitus and its relation to diabetic control parameters: an observational study, F1000Res, 2022;111112","journal-title":"F1000Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.12688\/f1000research.125446.1","article-title":"Medication-related burden among Iraqi patients with rheumatoid arthritis: an observational study","volume":"11","author":"Jwad RK, Kadhim DJ, Alosami HM, Shareef LG","year":"2022","unstructured":"20. Jwad RK, Kadhim DJ, Alosami HM, Shareef LG, Medication-related burden among Iraqi patients with rheumatoid arthritis: an observational study, F1000Res, 2022;111047","journal-title":"F1000Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy6030085","article-title":"Medication-related burden among patients with chronic disease conditions: perspectives of patients attending non-communicable disease clinics in a primary healthcare setting in Qatar. [master's thesis]","author":"Zidan A","year":"2017","unstructured":"21. Zidan A, Medication-related burden among patients with chronic disease conditions: perspectives of patients attending non-communicable disease clinics in a primary healthcare setting in Qatar. [master's thesis], Qatar University. College of Pharmacy, 2017;","journal-title":"Qatar University. College of Pharmacy"},{"issue":"3","key":"ref22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/pharmacy6030085","article-title":"Medication-related burden among patients with chronic disease conditions: perspectives of patients attending non-communicable disease clinics in a primary healthcare setting in Qatar","volume":"6","author":"Zidan A, Awisu A, El-Hajj MS, Al-Abdulla SA, Figueroa DCR, Kheir N","year":"2018","unstructured":"22. Zidan A, Awisu A, El-Hajj MS, Al-Abdulla SA, Figueroa DCR, Kheir N, Medication-related burden among patients with chronic disease conditions: perspectives of patients attending non-communicable disease clinics in a primary healthcare setting in Qatar, Pharmacy (Basel), 2018;6(3):85","journal-title":"Pharmacy (Basel)"},{"issue":"13","key":"ref23","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1097\/01.MIB.0000435442.07237.a4","article-title":"The burden of comedication among patients with inflammatory bowel disease","volume":"19","author":"Buckley JP, Kappelman MD, Allen JK, Van Meter SA, Cook SF","year":"2013","unstructured":"23. Buckley JP, Kappelman MD, Allen JK, Van Meter SA, Cook SF, The burden of comedication among patients with inflammatory bowel disease, Inflamm Bowel Dis, 2013;19(13):2725-2736","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"ref24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12876-022-02578-2","article-title":"Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study","volume":"22","author":"Mosli MH, Alsahafi M, Alsanea MN, Alhasani F, Ahmed M, Saadah O","year":"2022","unstructured":"24. Mosli MH, Alsahafi M, Alsanea MN, Alhasani F, Ahmed M, Saadah O, Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study, BMC Gastroenterol, 2022;22(1):487","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"ref25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1185\/030079908X260790","article-title":"The costs of Crohn\u2019s disease in the United States and other Western countries: a systematic review","volume":"24","author":"Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J","year":"2008","unstructured":"25. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J, The costs of Crohn\u2019s disease in the United States and other Western countries: a systematic review, Curr Med Res Opin, 2008;24(2):319-328","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"ref26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2036.2010.04234.x","article-title":"Systematic review: the costs of ulcerative colitis in Western countries","volume":"31","author":"Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J","year":"2010","unstructured":"26. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J, Systematic review: the costs of ulcerative colitis in Western countries, Aliment Pharmacol Ther, 2010;31(7):693-707","journal-title":"Aliment Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives","volume":"11","author":"Rawla P, Sunkara T, Raj JP","year":"2018","unstructured":"27. Rawla P, Sunkara T, Raj JP, Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives, J Inflamm Res, 2018;11215-226","journal-title":"J Inflamm Res"},{"issue":"1","key":"ref28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study","volume":"63","author":"Valk ME, Mangen MJ, Leenders M","year":"2014","unstructured":"28. Valk ME, Mangen MJ, Leenders M, Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study, Gut, 2014;63(1):72-79","journal-title":"Gut"},{"issue":"9","key":"ref29","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1007\/s00520-019-05247-5","article-title":"Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors","volume":"28","author":"Sutton AL, Salgado TM, He J, Hurtado-de-Mendoza A, Sheppard VB","year":"2020","unstructured":"29. Sutton AL, Salgado TM, He J, Hurtado-de-Mendoza A, Sheppard VB, Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors, Support Care Cancer, 2020;28(9):4147-4154","journal-title":"Support Care Cancer"},{"issue":"6","key":"ref30","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.3390\/ijerph18062825","article-title":"Impact of beliefs about medicines on the level of intentional non-adherence to the recommendations of elderly patients with hypertension","volume":"18","author":"\u015awi\u0105toniowska-Lonc N, Pola\u0144ski J, Mazur G, Jankowska-Pola\u0144ska B","year":"2021","unstructured":"30. \u015awi\u0105toniowska-Lonc N, Pola\u0144ski J, Mazur G, Jankowska-Pola\u0144ska B, Impact of beliefs about medicines on the level of intentional non-adherence to the recommendations of elderly patients with hypertension, Int J Environ Res Public Health, 2021;18(6):2825","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"ref31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.31351\/vol27iss2pp24-31","article-title":"Belief about medications among sample of Iraqi patients with inflammatory bowel disease","volume":"27","author":"Jebur NJ, Kadhim DJ, Firhan NM","year":"2018","unstructured":"31. Jebur NJ, Kadhim DJ, Firhan NM, Belief about medications among sample of Iraqi patients with inflammatory bowel disease, Iraq J Pharm Sci, 2018;27(2):32-41","journal-title":"Iraq J Pharm Sci"},{"issue":"3","key":"ref32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/hex.12046","article-title":"Burden of treatment for chronic illness: a concept analysis and review of the literature","volume":"18","author":"Sav A, King MA, Whitty JA, Kendall E, McMillan SS, Kelly F","year":"2015","unstructured":"32. Sav A, King MA, Whitty JA, Kendall E, McMillan SS, Kelly F, Burden of treatment for chronic illness: a concept analysis and review of the literature, Health Expect, 2015;18(3):312-324","journal-title":"Health Expect"},{"issue":"4","key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019413","article-title":"Development and validation of the multimorbidity treatment burden questionnaire (MTBQ)","volume":"8","author":"Duncan P, Murphy M, Man MS, Chaplin K, Gaunt D, Salisbury C","year":"2018","unstructured":"33. Duncan P, Murphy M, Man MS, Chaplin K, Gaunt D, Salisbury C, Development and validation of the multimorbidity treatment burden questionnaire (MTBQ), BMJ Open, 2018;8(4):","journal-title":"BMJ Open"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12875-019-0974-z","article-title":"Factors associated with patients' and GPs' assessment of the burden of treatment in multimorbid patients: a cross-sectional study in primary care","volume":"20","author":"Herzig L, Zeller A, Pasquier J, Streit S, Neuner-Jehle S, Excoffier S","year":"2019","unstructured":"34. Herzig L, Zeller A, Pasquier J, Streit S, Neuner-Jehle S, Excoffier S, Factors associated with patients' and GPs' assessment of the burden of treatment in multimorbid patients: a cross-sectional study in primary care, BMC Fam Pract, 2019;20(1):1-11","journal-title":"BMC Fam Pract"},{"issue":"6","key":"ref35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40271-016-0175-y","article-title":"Treatment burden and chronic illness: who is at most risk?","volume":"9","author":"Sav A, Whitty JA, McMillan SS, Kendall E, Kelly F, King MA","year":"2016","unstructured":"35. Sav A, Whitty JA, McMillan SS, Kendall E, Kelly F, King MA, Treatment burden and chronic illness: who is at most risk?, Patient, 2016;9(6):559-569","journal-title":"Patient"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/all-issues\/2024\/issue-8-2024\/original-article-issue-8-2024\/medication-related-burden-among-iraqi-patients-with-ulcerative-colitis-a-cross-sectional-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:39:57Z","timestamp":1737689997000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/all-issues\/2024\/issue-8-2024\/original-article-issue-8-2024\/medication-related-burden-among-iraqi-patients-with-ulcerative-colitis-a-cross-sectional-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["JMedLife-17-800"],"URL":"https:\/\/doi.org\/10.25122\/jml-2023-0342","relation":{},"ISSN":["1844-3117"],"issn-type":[{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}